Literature DB >> 11425312

Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain.

J G Karras1, M A Maier, T Lu, A Watt, M Manoharan.   

Abstract

Antisense oligonucleotides (ASOs) that bind target pre-mRNA with high affinity have been shown to alter splicing patterns and offer promise as therapeutics. Previous studies have shown that ASOs fully modified with 2'-O-methoxyethyl (2'-O-MOE) sugar residues redirect constitutive and alternative splicing of the murine interleukin-5 receptor-alpha (IL-5Ralpha) chain pre-mRNA in cells, resulting in inhibition of the membrane-bound isoform and enhanced expression of the soluble isoform. Here, we show that antisense peptide nucleic acids (PNAs) alter splicing of the IL-5Ralpha pre-mRNA in a fashion similar to their 2'-O-MOE-modified counterparts of the same sequence. Moreover, using PNA as the splicing modulator, the length of the antisense oligomer could be shortened from 20 to 15 nucleobase units to obtain a comparable effect. Treatment of cells with antisense PNA resulted in dose-dependent, specific downregulation of IL-5Ralpha membrane isoform mRNA expression and enhanced levels of the soluble IL-5Ralpha isoform transcript, with an EC50 equivalent to that observed in parallel with the corresponding 2'-O-MOE ASO. The pronounced activity of antisense PNAs in modulating IL-5Ralpha mRNA splicing observed in our study identifies these compounds as a promising new class of lower molecular weight splicing modulators.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425312     DOI: 10.1021/bi010263l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  PNA Technology.

Authors:  Peter E Nielsen
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.695

2.  Efficiency of cellular delivery of antisense peptide nucleic acid by electroporation depends on charge and electroporation geometry.

Authors:  Mette Joergensen; Birgit Agerholm-Larsen; Peter E Nielsen; Julie Gehl
Journal:  Oligonucleotides       Date:  2011-01-14

3.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

4.  Methods for assessing DNA hybridization of peptide nucleic acid-titanium dioxide nanoconjugates.

Authors:  Eric M B Brown; Tatjana Paunesku; AiGuo Wu; K Ted Thurn; Benjamin Haley; Jimmy Clark; Taisa Priester; Gayle E Woloschak
Journal:  Anal Biochem       Date:  2008-08-26       Impact factor: 3.365

5.  Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing.

Authors:  Andrew M Siwkowski; Leila Malik; Christine C Esau; Martin A Maier; Edward V Wancewicz; Klaus Albertshofer; Brett P Monia; C Frank Bennett; Anne B Eldrup
Journal:  Nucleic Acids Res       Date:  2004-05-17       Impact factor: 16.971

6.  Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2'-O-methyl G-clamp ribonucleoside analogues.

Authors:  Stephen C Holmes; Andrey A Arzumanov; Michael J Gait
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

Review 7.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 8.  Targeting RNA splicing for disease therapy.

Authors:  Mallory A Havens; Dominik M Duelli; Michelle L Hastings
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-03-19       Impact factor: 9.957

Review 9.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 10.  A chemical view of oligonucleotides for exon skipping and related drug applications.

Authors:  Peter Järver; Liz O'Donovan; Michael J Gait
Journal:  Nucleic Acid Ther       Date:  2013-10-30       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.